This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cole, S. P. C. Articles by Mirski, S. E. L. Search for Related Content PubMed PubMed Citation Articles by Cole, S. P. C. Articles by Mirski, S. E. L.

Non-P-glycoprotein-mediated Multidrug Resistance in a Small Cell Lung Cancer Cell Line: Evidence for Decreased Susceptibility to Drug-induced DNA Damage and Reduced Levels of Topoisomerase II¹

Department sof Oncology [S. P. C. C., J. H. G., S. E. L. M.], Biochemistry [E. R. C., J. H. G.], and Pharmacology and Toxicology [S. P. C. C., F. P. D.], Queen's University, Kingston, Ontario K7L 3N6, Canada

Data obtained from clinical samples suggest that non-P-glycoprotein mechanisms of multidrug resistance are likely to be important in small cell lung cancer. The H69AR cell line was derived from the H69 small cell lung cancer cell line by selection in doxorubicin (adriamycin) and does not overexpress P-glycoprotein as detected by monoclonal antibody C219 (S. E. L. Mirski et al., Cancer Res., 47: 2594, 1987). In the present study, we have used the polymerase chain reaction to verify that H69AR cells do not overexpress P-glycoprotein. Further, transport studies with radiolabeled daunomycin, VP-16, and vinblastine demonstrate that differences in net drug accumulation or efflux are not part of the resistance phenotype of H69AR cells. To determine if H69 and H69AR cells differ in their susceptibility to drug-induced DNA damage, DNA single-strand breaks (SSB) generated by VP-16 and Adriamycin were measured using the alkaline filter elution assay. Readily detectable SSB were produced in intact H69 cells by 5 µM VP-16, but 100 µM drug was required to cause similar damage in H69AR cells. H69AR cells were also resistant to SSB induction by Adriamycin. The formation of SSB by VP-16 was similarly reduced in isolated H69AR nuclei, indicating that resistance to this drug resides, at least in part, in the nucleus. No significant differences were observed in the rate or extent of repair of VP-16-induced DNA SSB in H69 and H69AR cells. The reduced susceptibility to drug-induced SSB may result from alterations in topoisomerase II, since less immunoreactive topoisomerase II was found in H69AR cells compared to H69 cells. However, changes in topoisomerase II cannot explain the resistance of H69AR cells to such drugs as the Vinca alkaloids and gramicidin D, indicating that multiple mechanisms contribute to drug resistance in this small cell lung cancer cell line.

¹ Supported by grants 2049 (S. P. C. C.) and 2215 (J. H. G.) from the National Cancer Institute of Canada and by grants from the Clare Nelson Bequest of Kingston General Hospital (J. H. G.) and the Ontario Thoracic Society (S. E. L. M., S. P. C. C.). F. P. D. was the recipient of a studentship from the Pharmaceutical Manufacturers Association of Canada and the Medical Research Council of Canada.

² To whom requests for reprints should be addressed, at Cancer Research Laboratories, Room 331, Botterell Hall, Queen's University, Kingston, Ontario K7L 3N6, Canada.

Received 3/ 5/91. Accepted 4/12/91.

This article has been cited by other articles:

				M. M. Shareef, B. Brown, S. Shajahan, S. Sathishkumar, S. M. Arnold, M. Mohiuddin, M. M. Ahmed, and P. M. Spring Lack of P-Glycoprotein Expression by Low-Dose Fractionated Radiation Results from Loss of Nuclear Factor-{kappa}B and NF-Y Activation in Oral Carcinoma Cells Mol. Cancer Res., January 1, 2008; 6(1): 89 - 98. [Abstract] [Full Text] [PDF]

				R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF]

				A. Rajagopal and S. M. Simon Subcellular Localization and Activity of Multidrug Resistance Proteins Mol. Biol. Cell, August 1, 2003; 14(8): 3389 - 3399. [Abstract] [Full Text] [PDF]

				S. Patel, A. U. Sprung, B. A. Keller, V. J. Heaton, and L. M. Fisher Identification of Yeast DNA Topoisomerase II Mutants Resistant to the Antitumor Drug Doxorubicin: Implications for the Mechanisms of Doxorubicin Action and Cytotoxicity Mol. Pharmacol., October 1, 1997; 52(4): 658 - 666. [Abstract] [Full Text]

				B. D. Stride, C. E. Grant, D. W. Loe, D. R. Hipfner, S. P. C. Cole, and R. G. Deeley Pharmacological Characterization of the Murine and Human Orthologs of Multidrug-Resistance Protein in Transfected Human Embryonic Kidney Cells Mol. Pharmacol., September 1, 1997; 52(3): 344 - 353. [Abstract] [Full Text]

				T. Sumizawa, Z.-S. Chen, Y. Chuman, K. Seto, T. Furukawa, M. Haraguchi, A. Tani, N. Shudo, and S.-I. Akiyama Reversal of Multidrug Resistance-Associated Protein-Mediated Drug Resistance by the Pyridine Analog PAK-104P Mol. Pharmacol., March 1, 1997; 51(3): 399 - 405. [Abstract] [Full Text] [PDF]

				H. TAKESHITA, M. C. GEBHARDT, D. S. SPRINGFIELD, K. KUSUZAKI, and H. J. MANKIN Experimental Models for the Study of Drug Resistance in Osteosarcoma: P-Glycoprotein-Positive, Murine Osteosarcoma Cell Lines J. Bone Joint Surg. Am., March 1, 1996; 78(3): 366 - 75. [Abstract] [Full Text]

				S. Cole, G Bhardwaj, J. Gerlach, J. Mackie, C. Grant, K. Almquist, A. Stewart, E. Kurz, A. Duncan, and R. Deeley Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science, December 4, 1992; 258(5088): 1650 - 1654. [Abstract] [PDF]

				K.-i. Ito, S. L. Olsen, W. Qiu, R. G. Deeley, and S. P. C. Cole Mutation of a Single Conserved Tryptophan in Multidrug Resistance Protein 1 (MRP1/ABCC1) Results in Loss of Drug Resistance and Selective Loss of Organic Anion Transport J. Biol. Chem., May 4, 2001; 276(19): 15616 - 15624. [Abstract] [Full Text] [PDF]